Nkarta (NKTX) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Nkarta (NASDAQ: NKTX) recently:

• 3/31/2026 – Nkarta had its price target lowered by Mizuho from $14.00 to $12.00. They now have an “outperform” rating on the stock.
• 3/28/2026 – Nkarta was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/27/2026 – Nkarta had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/26/2026 – Nkarta had its price target raised by Needham & Company LLC from $10.00 to $11.00. They now have a “buy” rating on the stock.

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.